BEA Introduces New Kratom Industry Standards and 3 Advisory Board Members

GMP Compliant Labeling of Kratom

Self-Regulation and Accreditation Process

The Botanical Education Alliance has recently welcomed three new seasoned Advisory Board members to our team. Going forward, they will be essential for the success of BEA’s new direction involving responsible industry standards and a formal accreditation process.

Given the recent turn of events with the DEA withdrawing their temporary Schedule 1 ban, the BEA has come to the conclusion that in the best interests of keeping kratom legal, the industry must direct its efforts towards self-regulation.

What role will the BEA have in this?

As a response to the improper labeling and unethical marketing trends that have long existed within the kratom industry, the BEA has decided to create a responsible industry accreditation process that will push companies to adhere to certain certification standards.

BEA GMP Complaint Label
(Example of GMP Compliant Labeling)

Our goal is to encourage vendors to follow the accreditation process so that kratom will avoid further scrutiny and comparisons to illegal synthetics, hallucinogens, and any other sort of drug claims or harmful substances. As large of an industry that kratom is, with profits ranging in the billions, it is time to act accordingly to set industry standards.

The process is still currently in the works and more details on it will be released in the coming months.

To help with this undertaking, we’ve taken on three qualified experts who are veterans in their respective fields.

Welcome 3 New Advisory Board Members (Kratom Experts)

“Each one of our new board members have extensive experience in topics ranging from drug policy reform, natural healing methods and opiate addiction just to name a few. Their diverse backgrounds and knowledge will be critical to our continued success with the DEA and FDA” says BEA board member, Angela Watson.

We begin with Pascal Tanguay, a Canadian who has been working with drug policy reform in Thailand for the past decade. Pascal has played a large part in improving the Thai Governments relationship with kratom, of which it was recently down scheduled to Category 2 from Category 5, a big victory.

Pascal Tanguay BEA Advisory Board

He has long been an advocate for kratom and has written many publications supporting its decriminalisation.

Our next Advisory Board member is Gregg Scharf. Gregg is a licensed Clinical Substance Abuse Counselor and currently practices in the medicated-assisted treatment field helping those who struggle with severe opiate addictions.

Gregg Scharf BEA Advisory Board

Gregg holds a master’s degree in mental health counseling from Viterbo University and hopes to attain his Licensed Professional Counselor accreditation in the near future. He brings to the table a multi-disciplinary approach in dealing with opiate addiction, of which kratom could potentially play a significant role in.

Last but not least, Dr. Jesse Mancini is a registered pharmacist and Clinical Trial Leader for CPH Biotech, a company that carries out clinical, toxicological and pharmacological research to study the relationship between various plants and humans. A few of the plants being researched are kratom, St. Johns Wort and Kava Kava.

Jesse is a graduate from the Massachusetts College of Pharmacy and while there, he completed an accelerated 6 year doctorate program, which piqued his interest in natural healing methods. As a proponent for healthy living through the cultivation of lifestyle and the careful use natural medicines, Jesse hopes to add his pharmacological knowledge of kratom to our team of experts.

For more information on our BEA team, please visit